Floatz logo

(S)-3,5-DICHLORO-N-((1-ETHYL-2-PYRROLIDINYL)METHYL)-6-HYDROXY-O-ANISAMIDE

Dementia

Sunnybrook Health Sciences CentreSmall moleculePhase 4 / ApprovedDormant
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
81/ 100

Competitive context

40 Active assets in the Dementia cohort.

Asset / SponsorPhaseRating
Sra-333
The University of Texas Health Science Center at San Antonio
Phase 4BBB
Risperdal
Hannover Medical School
Phase 4BBB
CITALOPRAM
Hannover Medical School
Phase 4BBB
Galantamine Hydrobromide
Janssen Pharmaceutica N.V., Belgium
Phase 3BB
Namenda
Zealand University Hospital
Phase 4BB

View all 50 →

Same molecule, other indications

(S)-3,5-DICHLORO-N-((1-ETHYL-2-PYRROLIDINYL)METHYL)-6-HYDROXY-O-ANISAMIDE is also rated in:

AnhedoniaDormant
BB
Indicative ·
65 / 100
View asset →
Major DepressionDormant
BB
Indicative ·
65 / 100
View asset →
psychotic disorderDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →